Literature DB >> 27777286

Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis.

Patrick Antonietti1, Benedikt Linder1, Stephanie Hehlgans2, Iris C Mildenberger3, Michael C Burger3, Simone Fulda4,5,6, Joachim P Steinbach3,5, Florian Gessler7, Franz Rödel2,5, Michel Mittelbronn5,8, Donat Kögel9,5.   

Abstract

Malignant gliomas exhibit a high intrinsic resistance against stimuli triggering apoptotic cell death. HSF1 acts as transcription factor upstream of HSP70 and the HSP70 co-chaperone BAG3 that is overexpressed in glioblastoma. To specifically target this resistance mechanism, we applied the selective HSF1 inhibitor KRIBB11 and the HSP70/BAG3 interaction inhibitor YM-1 in combination with the pan-Bcl-2 inhibitor AT-101. Here, we demonstrate that lentiviral BAG3 silencing significantly enhances AT-101-induced cell death and reactivates effector caspase-mediated apoptosis in U251 glioma cells with high BAG3 expression, whereas these sensitizing effects were less pronounced in U343 cells expressing lower BAG3 levels. KRIBB11 decreased protein levels of HSP70, BAG3, and the antiapoptotic Bcl-2 protein Mcl-1, and both KRIBB11 and YM-1 elicited significantly increased mitochondrial dysfunction, effector caspase activity, and apoptotic cell death after combined treatment with AT-101 and ABT-737. Depletion of BAG3 also led to a pronounced loss of cell-matrix adhesion, FAK phosphorylation, and in vivo tumor growth in an orthotopic mouse glioma model. Furthermore, it reduced the plating efficiency of U251 cells in three-dimensional clonogenic assays and limited clonogenic survival after short-term treatment with AT-101. Collectively, our data suggest that the HSF1/HSP70/BAG3 pathway plays a pivotal role for overexpression of prosurvival Bcl-2 proteins and cell death resistance of glioma. They also support the hypothesis that interference with BAG3 function is an effective novel approach to prime glioma cells to anoikis. Mol Cancer Ther; 16(1); 156-68. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27777286     DOI: 10.1158/1535-7163.MCT-16-0262

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  28 in total

Review 1.  Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.

Authors:  Georg Karpel-Massler; Chiaki Tsuge Ishida; Yiru Zhang; Marc-Eric Halatsch; M-Andrew Westhoff; Markus D Siegelin
Journal:  Expert Opin Drug Discov       Date:  2017-07-20       Impact factor: 6.098

2.  Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.

Authors:  Vivian Adamski; Christina Schmitt; Florian Ceynowa; Rainer Adelung; Ralph Lucius; Michael Synowitz; Kirsten Hattermann; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-01       Impact factor: 4.553

3.  Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells.

Authors:  Moiken Mehner; Carolin Kubelt; Vivian Adamski; Christina Schmitt; Michael Synowitz; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-16       Impact factor: 4.553

4.  Proteomics analysis of proteins interacting with heat shock factor 1 in squamous cell carcinoma of the cervix.

Authors:  Lingli Zhang; Zhe Hu; Ying Zhang; Jinzhi Huang; Xuefen Yang; Jiafeng Wang
Journal:  Oncol Lett       Date:  2019-06-27       Impact factor: 2.967

5.  Heat shock factor 1 in brain tumors: a link with transient receptor potential channels TRPV1 and TRPA1.

Authors:  Athanasia Moutafidi; George Gatzounis; Vassiliki Zolota; Martha Assimakopoulou
Journal:  J Mol Histol       Date:  2021-09-30       Impact factor: 2.611

Review 6.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

Review 7.  HSF1 as a Cancer Biomarker and Therapeutic Target.

Authors:  Richard L Carpenter; Yesim Gökmen-Polar
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

8.  Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.

Authors:  Thomas R Reich; Maja T Tomicic; Christian Schwarzenbach; Juliana Brandstetter Vilar; Sven Unger; Fabian Mühlhäusler; Teodora Nikolova; Alicia Poplawski; H Irem Baymaz; Petra Beli; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2021-06-08       Impact factor: 9.261

Review 9.  The Multifaceted Role of HSF1 in Pathophysiology: Focus on Its Interplay with TG2.

Authors:  Luca Occhigrossi; Manuela D'Eletto; Nickolai Barlev; Federica Rossin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

Review 10.  The role of BAG3 in health and disease: A "Magic BAG of Tricks".

Authors:  Heng Lin; Shon A Koren; Gregor Cvetojevic; Peter Girardi; Gail V W Johnson
Journal:  J Cell Biochem       Date:  2021-05-14       Impact factor: 4.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.